FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to the pharmaceutical industry and is a dietary supplement containing Aspergillus niger aspergilloglutamic peptidase, prolyl-endopeptidase and dietary suitable excipients, as well as a pharmaceutical composition for the treatment of gluten intolerance in humans, containing Aspergillus niger aspergilloglutamic peptidase, prolyl endopeptidase and pharmaceutically suitable excipients.
EFFECT: invention provides for the hydrolysis of alpha-amylase/trypsin inhibitors in order to treat diseases associated with innate immune response in humans, or enables to slow down the manifestations of these diseases.
20 cl, 6 ex, 2 tbl, 5 dwg
Authors
Dates
2018-11-07—Published
2014-12-11—Filed